A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosarcoma
Public ClinicalTrials.gov record NCT07477457. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
OstEvo - Osteosarcoma Evolves
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The researchers are doing this study to find out whether adding gefitinib, trametinib, disulfiram, and sunitinib to standard chemotherapy is a more effective treatment approach for people with osteosarcoma than standard chemotherapy on its own. The researchers will also look at the safety of adding these drugs to standard chemotherapy. The researchers will also use the additional research biopsies from Cohort 1 participants to learn more about how osteosarcoma survives during chemotherapy.
Study identification
- NCT ID
- NCT07477457
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 45 participants
Conditions and interventions
Conditions
Interventions
- Methotrexate Drug
- Doxorubicin Drug
- Cisplatin Drug
- Gefitinib Drug
- Trametinib Drug
- Disulfiram Drug
- Sunitinib Drug
- Ifosfamide Drug
- Biopsy Procedure
Drug · Procedure
Eligibility (public fields only)
- Age range
- 6 Years to 49 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 10, 2026
- Primary completion
- Feb 29, 2028
- Completion
- Mar 10, 2028
- Last update posted
- Mar 16, 2026
2026 – 2028
United States locations
- U.S. sites
- 7
- U.S. states
- 2
- U.S. cities
- 7
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities) | Basking Ridge | New Jersey | 07920 | Recruiting |
| Memorial Sloan Kettering at Monmouth (Limited Protocol Activities) | Middletown | New Jersey | 07748 | Recruiting |
| Memorial Sloan Kettering at Bergen (Limited Protocol Activities) | Montvale | New Jersey | 07645 | Recruiting |
| Memorial Sloan Kettering at Suffolk-Commack (Limited Protocol Activities) | Commack | New York | 11725 | Recruiting |
| Memorial Sloan Kettering at Westchester (Limited Protocol Activities) | Harrison | New York | 10604 | Recruiting |
| Memorial Sloan Kettering Cancer Center (All Protocol Activites) | New York | New York | 10065 | Recruiting |
| Memorial Sloan Kettering at Nassau (Limited Protocol Activities) | Uniondale | New York | 11553 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07477457, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 16, 2026 · Synced Sep 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07477457 live on ClinicalTrials.gov.